Episode Details
Back to Episodes
Jun 11, 2026 | Takeda Zasocitinib Beats Sotyktu in Head-to-Head Phase 3; Summit Pulls $500M Offering
Description
Zasocitinib hits 35% complete skin clearance at week 16,topping Sotyktu by more than 2.5x in Takeda's head-to-head Phase 3. Plus: Novartis validates its $12B Avidity AOC platform in FSHD, Summit withdraws $500M offering, and Genentech reshapes its research organization.
Visit us at www.thepharmacloseout.com
pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, zasocitinib, Takeda, Sotyktu, deucravacitinib, Bristol Myers Squibb, TYK2, plaque psoriasis, PASI 100, Novartis, Avidity Biosciences, AOC, muscular dystrophy, FSHD, SummitTherapeutics, ivonescimab, Kardigan, IPO, J&J, nipocalimab, Imaavy, wAIHA, Genentech, Roche, Vishva Dixit, Camurus, Oclaiz, acromegaly, CRL, Sensorion, Regeneron, hearing loss, Ethyreal, thyroid eye disease, Teva, Astellas, Xtandi, BMS